Seminario sobre microencapsulación de células y biomoléculas. Madrid, 23 de abril de 2012
General information
Thursday, 12 April 2012 11:49
There are no translations available.

El próximo lunes, 23 de abril, Biomedal, junto con el Instituto Universitario de Farmacia Industrial, impartirá un seminario sobre conceptos básicos de microencapsulación monodispersa enfocado en aplicaciones del área de la microbiología, terapia celular y tecnología farmacéutica. El objetivo de este seminario es mostrar una innovadora tecnología para microencapsular células, bacterias y biomoléculas que mantienen su funcionalidad, basada en la tecnología Flow Focusing® mediante el equipo portatil de microencapsulación monodispersa, Cellena®.

Para más información, pinche aqui

Biomedal and Ingeniatrics signs a distribution agreement for Cellena® bioencapsulator.
About Ingeniatrics
Wednesday, 21 March 2012 12:00

Dr. Angel Cebolla Ramirez and Mr. Joaquin Gómez Moya

Biomedal SL and Ingeniatrics have signed a strategic distribution agreement. Biomedal will be the global distributor of Ingeniatric's portable Bioencapsulation device, Cellena®. The agreement was signed on Friday, March 16th at Ingeniatrics’s facilities by both companies CEOs Dr. Angel Cebolla Ramirez, Biomedal, and Mr. Joaquin Gómez Moya, Ingeniatrics.


Cellena® is a user-friendly, portable device that makes unneeded the use of autoclave as it is provided with sterile disposable nozzles. Nonetheless it is aimed to a highly specialized market: e.g. stem cells researchers; it is a complex sales process that requires a distributor like Biomedal. This is a well known biotechnology company with a seasoned sales force and whose mission is to develop and commercialize new biomedical technologies, services and products for research, bioindustry and diagnostics. Biomedal enhances the talent of its team with the collaboration of an outstanding and growing network of international scientists and technologists, and directs its efforts to satisfy its customers.

The excellent market position of this company based in Seville ensures short-term success in Emerging markets as cell therapy or stem cell research

Bioencapsulation Step forward

“This agreement confirms the Ingeniatrics effort  to settle down as one of the main microencapsulation key-players. Cellena® would improve some assays and diagnostics in an order of magnitude and can be utilized in combination with cytometers like - for instance - COPAS and Biosorter” indicated Ángel Cebolla.

Biomedal will offer this device among other products to improve the society quality of life and has started proposing Bioencapsulation as a cost-effective solution to the some of the most important research groups in the world. On the other hand, Ingeniatrics still owns the Flow Focusing® technology and stays sole manufacturer of Cellena®.

For further information please click here

Catálogo Interactivo de la OTRI
General information
Thursday, 15 March 2012 09:02
There are no translations available.


La Oficina de Transferencia de Resultados de Investigación (OTRI) ha elaborando un catálogo acerca de las Spin off de la Universidad de Sevilla.Este catálogo pretende hacer lo más atractiva posible la información publicada de cada compañía, destacando el origen tecnológico de las mismas y haciendo especial hincapié en patentes, servicios, productos y proyectos de investigación.

"Desde el Vicerectorado de Transferencia Tecnológica de la Universidad de Sevilla se han impulsado actuaciones que falicitan la valorización del conocimiento generado por la Universidad, favoreciendo el proceso de transferencia de conocimeinto universitario a la sociedad y dando especial relevancia  a la creación de empresas Spin Off como herramienta eficaz de aplicación del conocimiento generado en la institución"

Para más información, pinche aqui

AENOR certificates Ingeniatrics' Quality Control and Environment management according to ISO 9001 and 14001.
About Ingeniatrics
Tuesday, 13 March 2012 10:43

Lola Romero Guzmán, Ingeniatrics's QA & Environment Manager.

On March 2012, the technological company Ingeniatrics, specialized in design and production of micro and nano particles and the equipment to produce them, has attained ISO 9001 and ISO 14001 certificates issued by AENOR, acknowledging that Ingeniatrics’ environmental and quality management systems fully meet international requirements according to UNE-EN-ISO 9001:2008 and UNE-EN-ISO 14001:2004 after the corresponding audits.


The audit was carried out by a team of AENOR, Asociación Española de Normalización y Acreditación, which is in possession of close to 190 national and international accreditations including ENAC's. ENAC is the Spanish Accreditation Body which in turns belongs the international quality certification accreditation system and is recognized in the UE, EFTA, USA, Canada, Japan, China, Australia... Up to 60 countries.

Continuous improvement in the long run:

Pilot plant’s construction ended in December 2011, so validation tests, operational and procedures qualification started up immediately after that. Simultaneously quality control projects had started on March 2011, going through different phases of study, project, documentation, procedures definition, procedures deployment, reviews, mandatory pre-auditory and finally - on December 2011 and January 2012 - the audit itself.  

Ingeniatrics' quality control and environmental management was led by Lola Romero who indicates “this milestone is not the end, but the beginning of a way of continuous improvement which reaffirms the company position in the market”. Ingeniatrics' principals have targeted chemical, pharmaceutical and food major corporations interested in the applications of Flow Focusing and Flow Blurring microparticles technology.


Certification for pharma field is in progress. Current certificate scope is: "Provision of microencapsulation services for Chemicals and Nutrition industries. Design and manufacturing of micro- and nano- particles. Design and manufacturing of nebulizers and atomization systems."
Ingeniatrics and Aradigm sign a licensing agreement to apply Flow Focusing® and Flow Blurring® technology to inhalation drugs.
About Ingeniatrics
Tuesday, 06 March 2012 08:02

The technological Ingeniatrics and Aradigm, a pulmonary pharmaceutical industry pioneer, signed a new agreement in February, 2012. By this, Aradigm is licensed by Ingeniatrics to develop and operate in the field of medicaments administration to or through respiratory tract using flow focusing and flow blurring technology. 


Aradigm's multidisciplinary team led by Dr. Igor Gonda and David Cipolla has experience at developing a variety of pharmaceutical and health care products and launching them to the market.

Aradigm gets an exclusive, world-wide license on Ingeniatrics's technology to develop, make, use, sell, and  offer for sale drugs delivered by inhalation, including drugs for  severe respiratory disease treatment.


Enhanced Licensees support:

Once Ingeniatrics had reached agreements with Flow Pharma and the University of Seville, this agreement with Aradigm confirms Ingeniatrics’ control and strengthen its position. Due to this, the microencapsulation company offers a stable, safe and simplified framework to all its licensees and their sub- licensees in order to ensure their business model.



Optimized Intellectual Property management:


Ingeniatrics is currently focused on scaling its technologies up, enhancing its capacity to offer services and products making use of its brand-new three hundred square meters microencapsulation pilot-plant, which is made up of three separate rooms for Pharma (registered as "cleanroom" or ISO 7 white room), Food and Chemistry.

By virtue of this agreement, Ingeniatrics will be the only Flow Focusing® and Flow Blurring® patents manager world-wide. Alongside with other previous agreements, this one grants to Ingeniatrics a solid base to strategize the best course of action to protect its microencapsulation and nebulization Intellectual Property.

Optimisation of alginate capsules for intravitreous administration utilising FlowFocusing®.
About Ingeniatrics
Monday, 05 March 2012 09:41

The present study led by Dr. Jose Luis Pedraz's research group (University of Vitoria) covers a comprehensive technological development introducing the Ingeniatrics's Flow Focusing System® as a promising technique to obtain highly monodisperse 100 μm alginatepoly-L-lysine-alginate (APA) microcapsules. These preliminary results open the door to further investigations, where the effectiveness of this technology might be tested in a retinopathy model.


The field of cell microencapsulation is advancing rapidly. Particle size plays a critical role in terms of biocompatibility and limits decisively its applicability. Producing reduced size microcapsules involves broadening the possibilities to employ this technology in the treatment of many disorders. Nervous system diseases (NSD) represent a clear example of that.


Please, click here to read the entire paper
<< Start < Prev 1 2 3 4 5 6 7 8 9 10 Next > End >>

Page 6 of 20